JC10 Rec'd PCT/PTO 1 DEC 2001

Attorney's Docket No. 004101-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Maurice ISRAEL et al.)
Application No.: UNASSIGNED (Corresponds to PCT/FR00/01612)) Group Art Unit: UNASSIGNED)
International Filing Date: 9 JUNE 2000)) Examiner: UNASSIGNED
For: PHARMACEUTICAL COMPOSITION)
COMPRISING NO OR AT LEAST A)
NO DONOR COMPOUND OR)
ANOTHER COMPOUND CAPABLE)
OF RELEASING OR INDUCING NO)
FORMATION IN CELLS)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Copies of the references have been forwarded to the U.S. Designated/Elected Office by WIPO.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

Information Disclosure Statement Application No. <u>Unassigned</u> Attorney's Docket No. <u>004101-003</u> Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialled copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

Teresa Stanek Rea

Registration No. 30,427

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: DECEMBER 10, 2001

10/009198 SHEET 1 OF 3 SHEET 1 OF 3 SHEET 1 OF 3 ON THEN NO. DEC 2001

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKTING I REC'U	APPLICATION NOW DEC 20 UNASSIGNED
APPLICANT Maurice ISRAEL et al.	
INT'L FILING DATE	GROUP UNASSIGNED

			U.S. PATENT DOCUMEN	IS				
	U.S. Patent Do	cument			Data of Bubli	aatian		
Examiner	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document			Date of Publication (MM-DD-YYYY)		
Initials	5,885,621		H.C. Alvin et al.		03/23/19	999		
	0,000,021							
				FNTC		···		
			OREIGN PATENT DOCUM	ENTS				
	Foreign Patent	Document Kind Code	4	}	Date of Publication	Trans	lation	
Examiner Initials	Number	(if known)	Country		(MM-DD-YYYY)	Yes	n	
	WO 97/33173		PCT		09/12/1997		 —	
	DE 29709820		GERMANY		07/31/1997		├	
	WO 96/02241		PCT		02/01/1996		├	
	WO 99/01427		PCT		01/14/1999		┼	
	WO 98/13358		PCT		04/02/1998		╄	
	EP 0 870 763		EUROPE		10/14/1998		↓_	
	WO 97/25984		PCT		07/24/1997		上	
		NON	PATENT LITERATURE DO	CUMENT	s			
	Include	-6	CARITAL LETTERS) title o	f the article	(when appropriate), title o	f the		
Examiner	item (book	, magazine, jo	urnal, serial, symposium, catalog publisher, city and/or country	i, etc.), date	, page(s), volume-issue na	mber(s),		
Initials		"Fff 07 A	TP and amino acid mixtures on p	rogressive n	nuscular dystrophy," SAPP	ORO IGA	ΚU	
	TACCUL (1065) 27	284-97 XP0	02131218					
D.S. BREDT, "Endogenous nitric oxide synthesis: Biological functions and pathophysiology," FREE								
	I.W. HAYCOCK et al., "Oxidative damage to muscle protein in Duchenne muscular dystropny," Neurone Fort, (199							
	Not 0 No. 1 no. 257-361 XP000879014							
D.S. CHAO et al.: "Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrohpy," (1996), 184(2), pp. 609-618								
	L. ROMAULD et al.: "Neuronal nitric oxide synthase isoforms.alpha.and.mu. are closely related calpain-sensitive proteins," MOL. PHARMACOL. (1998), 54(2), pp. 305-312 A. DECRORY et al.: "Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase a sarcolemma of mdx4cv skeletal muscle fibers," GENE THERAPY, (1998), 5(1), pp. 59-64							
							; at 1	
	G B AZZENA et a	.: "Nitric oxid	e regenerates the normal colonic 9), 261, (1-2), pp. 9-12	peristaltic	activity in mdx dystrophic	mouse,"		
	NEUROSCIENCE L	E11EN3, (133	011 20 17 (1 211 pp. 0 12					
Examiner			Dat	te				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	SHEET 2.05FB	ሳስስነ
ATTORNEY'S DKT NOW 10 110	UNASSIGNED	2001
APPLICANT Maurice ISRAEL et al.		
INT'L.FILING DATE 9 June 2000	GROUP UNASSIGNED	

		u	.S. PATENT DOCUM	ENTS				
	U.S. Patent Document				Dana of Bulbli	D f Bublication		
Examiner Initials	Kind Code Number (if known)		Name of Patentee or Applicant of Cited Document			Date of Publication (MM-DD-YYYY)		
			REIGN PATENT DOC	UMENTS		Т		
	Foreign Patent				Date of Publication	Trans	lation	
Examiner Initials	Kind Code Number (if known)		Country		(MM-DD-YYYY)		no	
	WO 95/28377		PCT		10/26/1995	-	-	
						_	-	
							<u> </u>	
			ATENT LITERATURE			the		
Examiner Initials	item (book	, magazine, jourr	nal, serial, symposium, cat publisher, city and/or cou	alog, etc.), da Intry where p	le (when appropriate), title o ate, page(s), volume-issue nu ublished.			
HILLIO	(4000) 0E/2E no	15000-15095			," PROC. NAT'L. ACAD. SCI		_	
	CHAUBOURT et al.	: "Nitric oxide a			utrophin at the" NEUROBIC			
	119/4) PP 501-508	3			e cell anemia", NUTR. RES	. (N.Y.) (1999)	
	A.N. SCHECHTER:	"NO Therapy,"	JOURNAL OF CLIN. INVE	STIGATION (1	997), 100/5, PP. 955-956	Г. (1997)		
	C. ALVIN HEAD et al.: "Low concentrations of nitric oxide increase oxygen affinity", J. CLIN. INVEST. (1997), 100(5), PP. 1193-1198 S.P. PERRINE et al.: "Butyrate-induced reactivation of the fetal globin genes", EXPERIENTIA, BIRKHAUSER VERLAG BASEL, CH. Vol. 49, No. 2 (1993) PP. 133-137 R. PACELLI et al.: "Hydroxyurea reacts with heme proteins to generate nitric oxide," LANCET (1996), 347/9005 (900 C. MORRIS et al.: "Effects of L-arginine therapy on nitric oxide production in patients", BLOOD (11/15/1998), Vol.							
							. Vol.	
	IOO NA 10 Cumpl	1 Dart 1_2 nn	695A					
	C.O. ENWONWU: 997-998	"Increased meta	abolic demand for arginine	in sickle cell	anemia," MED. SCI. RES. (19	031, 17(2	201, 11	
Examiner				Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

10/009198

'Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT No 1000	YAPPLICATION NO. UNASSIGNED
APPLICANT Maurice ISRAEL et al.	
INT'L. FILING DATE 9 June 2000	GROUP UNASSIGNED

— Т			J.S. PATENT DOCUI				
	U.S. Patent	Document					
Examiner Initials	Number	Kind Code (if known)	Name of Patentee of Cited Do		Date of Public (MM-DD-YY		
- Intitude							
		 FO	REIGN PATENT DO	CUMENTS			
 1	Foreign Pater						
Examiner	Number	Kind Code (if known)	Country		Date of Publication (MM-DD-YYYY)	Trans Yes_	lation no
Initials	Number	(II KHOVII)	- Journal of the second of the				<u> </u>
						-	-
						_	
						1	<u> </u>
							<u> </u>
			ATENT LITERATURE			41	
Examiner	Includ item (bod	de name of author ok, magazine, jour	(in CAPITAL LETTERS), t nal, serial, symposium, ca publisher, city and/or co	atalog, etc.), d	cle (when appropriate), title of ate, page(s), volume-issue num published.	the nber(s),	
Initials	G.D. SHER et al.:	"Extended thera 2/24, PP. 1606-1	py with intravenous argin	ine butyrate in	patients with beta", NEW E	NG. J. C)F
	C.R. MORRIS et a	al.: "L-arginine the	erapy paradoxically decre VOL. 45, NO. 4, PART 2,	ases nitric oxid	de production in patients with s	sickle ce	11
	A.M. ATZ et al.: VOL. 87, NO. 4,	"Inhaled nitric ox	ide in sickle cell disease v	vith acute che	st syndrome," ANESTHESIOLO	GY (199) 7),
	VOL. 07, NO. 17						
				<u> </u>			
	 						
Examiner				Date Considered			